Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Employees

111

Sector

Biotechnology & Medical Research

Calendar

05/03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/26/12	10.61 $	-2.66%	5,45,765
09/26/09	10.90 $	-2.15%	7,46,080
08/26/08	11.14 $	+1.83%	8,76,676
07/26/07	10.94 $	+7.68%	7,22,695
06/26/06	10.16 $	+1.70%	6,21,966

Delayed Quote Nasdaq, January 13, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.61USD

Average target price

29.43USD

Spread / Average Target

+177.41%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 13/01/2026 am IST			5-day change	1st Jan Change
10.61 ^USD	-2.66%		+6.21%	+2.51%

12/01	XOMA Royalty Corporation Announces CFO Changes	CI
09/12	Cullinan Therapeutics, Inc. - Special Call

Capitalization	63Cr 54Cr 50Cr 47Cr 87Cr 5.65TCr 93Cr 574.99Cr 226.02Cr 2.7TCr 235.06Cr 230.24Cr 9.91TCr	P/E ratio 2025 *	-3.02x	P/E ratio 2026 *	-3.56x
Enterprise value	26Cr 23Cr 21Cr 20Cr 37Cr 2.37TCr 39Cr 241.52Cr 95Cr 1.14TCr 99Cr 97Cr 4.16TCr	EV / Sales 2025 *	35.2x	EV / Sales 2026 *	9.76x
Free-Float	94.38%	Yield 2025 *	-	Yield 2026 *	-

12/01	XOMA Royalty Corporation Announces CFO Changes	CI
09/12	Cullinan Therapeutics, Inc. - Special Call
09/12	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash Meeting	CI
08/12	Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses	MT
08/12	Cullinan Therapeutics says phase 1 CLN-049 monotherapy demonstrates promising efficacy	RE
01/12	Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia	CI
01/12	Cullinan Therapeutics receives FDA fast track designation for CLN-049	RE
01/12	Cullinan Therapeutics Investigational Acute Myeloid Leukemia Therapy Receives US FDA Fast-Track Designation	MT
22/11	Cullinan Therapeutics - Cullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617	RE
20/11	Cullinan, Taiho Submit New Drug Application for Zipalertinib in Lung Cancer	MT
20/11	Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics initiate rolling submission of new drug application to US FDA	RE
20/11	Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	CI
06/11	Cullinan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

13/25/13	Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025	CI
07/21/07	CULLINAN ONCOLOGY : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating	MT
04/21/04	CULLINAN ONCOLOGY : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating	MT
04/21/04	CULLINAN ONCOLOGY : SVB Leerink Adjusts Price Target on Cullinan Management to $54 From $48, Maintains Outperform Rating	MT
27/21/27	CULLINAN ONCOLOGY : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target	MT

Cullinan Therapeutics, Inc. Share Price

Equities

CGEM

US2300311063

Biotechnology & Medical Research

Valuation: Cullinan Therapeutics, Inc.

Chart: Cullinan Therapeutics, Inc.

Latest news: Cullinan Therapeutics, Inc.

Last Transcript: Cullinan Therapeutics, Inc.

Analysts' recommendations: Cullinan Therapeutics, Inc.

Press Releases: Cullinan Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cullinan Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

08/01	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones	GL
08/01	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones	AQ
09/12	Cullinan Therapeutics : ASH 2025 Analyst and Investor Event Presentation (2ed0bf)	PU
08/12	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting	GL
01/12	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia	GL

1 day	-2.66%
1 week	+6.21%
Current month	+2.51%
1 month	-10.99%
3 months	+43.38%
6 months	+37.79%
Current year	+2.51%

1 week	10.04	11.6
1 month	9.41	12.09
Current year	9.41	11.6
1 year	5.68	13.33
3 years	5.68	30.19
5 years	5.68	59.85
10 years	5.68	59.85

Manager	Title	Age	Since
Nadim Ahmed CEO	Chief Executive Officer	58	18/10/2021
Mary Fenton DFI	Director of Finance/CFO	62	29/04/2024
Jacquelyn Sumer CMP	Compliance Officer	48	15/08/2022

Director	Title	Age	Since
Anthony Adam Rosenberg CHM	Chairman	72	01/04/2020
Stephen Webster BRD	Director/Board Member	65	01/09/2020
Nadim Ahmed BRD	Director/Board Member	58	18/10/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CULLINAN THERAPEUTICS, INC.	-2.66%	+6.21%	-5.18%	-2.30%	63Cr
ARGENX SE	+4.05%	+2.34%	+8.16%	+90.32%	4.8TCr
WUXI APPTEC CO., LTD.	-0.40%	+4.35%	+84.93%	+8.53%	4.2TCr
INSMED INCORPORATED	-4.69%	-4.27%	+157.04%	+768.57%	3.58TCr
BIONTECH SE	+2.33%	+5.50%	-16.83%	-31.61%	2.56TCr
GENMAB A/S	-0.28%	+7.96%	+38.84%	-20.75%	2.08TCr
WUXI BIOLOGICS (CAYMAN) INC.	+5.85%	+18.68%	+135.38%	-41.71%	1.99TCr
SUMMIT THERAPEUTICS INC.	-13.41%	-2.29%	-4.54%	+323.88%	1.31TCr
AKESO, INC.	-4.36%	+2.99%	+117.69%	+162.46%	1.49TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.68%	+11.30%	+185.68%	-	1.46TCr
Average	-0.22%	+4.65%	+70.12%	+139.71%	2.35TCr
Weighted average by Cap.	+0.18%	+2.93%	+72.44%	+166.61%

	2025 *	2026 *
Net sales	74.82L 64.07L 59.58L 55.55L 1.04Cr 67Cr 1.11Cr 6.86Cr 2.7Cr 32Cr 2.81Cr 2.75Cr 118.28Cr	2.48Cr 2.13Cr 1.98Cr 1.84Cr 3.44Cr 223.68Cr 3.69Cr 23Cr 8.95Cr 107.01Cr 9.31Cr 9.12Cr 392.36Cr
Net income	-21Cr -18Cr -17Cr -16Cr -30Cr -1.92TCr -32Cr -195.89Cr -77Cr -920.74Cr -80Cr -78Cr -3.38TCr	-19Cr -16Cr -15Cr -14Cr -27Cr -1.73TCr -29Cr -176.35Cr -69Cr -828.88Cr -72Cr -71Cr -3.04TCr
Net Debt	-36Cr -31Cr -29Cr -27Cr -50Cr -3.28TCr -54Cr -333.47Cr -131.08Cr -1.57TCr -136.33Cr -133.53Cr -5.75TCr	-38Cr -33Cr -31Cr -29Cr -53Cr -3.47TCr -57Cr -352.87Cr -138.71Cr -1.66TCr -144.26Cr -141.3Cr -6.08TCr